Corcept Therapeutics price target raised to $131 from $128 at Piper Sandler
Piper Sandler analyst David Amsellem raised the firm’s price target on Corcept Therapeutics (CORT) to $131 from $128 and keeps an Overweight ...
Corcept Therapeutics: New PROC SOC Treatment Option With Relacorilant Data Release
Corcept's relacorilant hits phase 3 trial success in ovarian cancer, lifting shares 90%. Click here to find out why I rate ...
Corcept Therapeutics Stock (CORT) Rockets Up 100% After Groundbreaking Cancer Trial Success
Corcept Therapeutics (CORT) stock shot up over 100% yesterday as markets reacted to the company’s announcement of promising outcomes from its ...
HC Wainwright Has Bullish Forecast for CORT FY2026 Earnings
Investment analysts at HC Wainwright increased their FY2026 EPS estimates for shares of Corcept Therapeutics in a research note issued on Monday, March 31st. HC Wainwright analyst S. Ramakanth now ...
Corcept's ovarian cancer drug cuts disease progression in study, shares jump
Corcept Therapeutics said on Monday its experimental drug in combination with chemotherapy helped delay progression of a type ...
Why Corcept Therapeutics Incorporated (CORT) Went Up On Monday?
In this article, we are going to take a look at where Corcept Therapeutics Incorporated (NASDAQ:CORT) stands against other ...
Fierce Biotech3d
Corcept's investigational oral therapy cuts ovarian cancer progression by 30%, teeing up FDA filing
Corcept Therapeutics’ oral antiglucocorticoid plus chemotherapy slashed risk of ovarian cancer progression by 30% compared to ...
Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...
American Association of Individual Investors2d
Which Is a Better Investment, Corcept Therapeutics Incorporated or Zoetis Inc. Stock?
Learn more about whether Corcept Therapeutics Incorporated or Zoetis Inc. is a better investment based on AAII's A+ Investor ...
GlobalData on MSN3d
Corcept’s Phase III trial of ovarian cancer therapy shows PFS improvement
The trial outcomes are said to support a new drug application in the US and a European marketing authorisation application.
American Association of Individual Investors2d
Which Is a Better Investment, Corcept Therapeutics Incorporated or Royalty Pharma plc Stock?
Learn more about whether Corcept Therapeutics Incorporated or Royalty Pharma plc is a better investment based on AAII's A+ ...
Winners and wishers: 9 potential Bay Area drug approvals coming this year
Three other Bay Area companies — Mirum Therapeutics Inc. (Nasdaq: MIRM), Soleno Therapeutics Inc. (Nasdaq: SLNO) and Exelixis ...